EU Commission granted orphan drug status for SENS-401

Release Date: 10-Dec-2016

Sensorian pharmaceuticals announced that European Commission has granted orphan drug designation in Europe for SENS-401 for the treatment of sudden sensorineural hearing loss. The European Commission grants orphan medicinal product status to provide incentives to develop medicinal products to treat, prevent or diagnose diseases or conditions that affect no more than five in 10,000 persons in the EU. The orphan medicinal product designation provides the company and its drug with certain benefits and incentives in the EU, including a period of market exclusivity of 10 years after the market approval, free consultation and scientific advice on contact with European Medicinal Agency.


For Orphan Drug Clinical Insight Reports Contact:


Need custom market research solution? We can help you with that too.